Eosinophilic Esophagitis Drug Development- Pipeline Analysis Report

Eosinophilic Esophagitis Drug Development- Pipeline Analysis Report

  • May 2018 •
  • Report ID: 5390318 •
  • Format: PDF
Eosinophilic Esophagitis (EoE) represents the allergic inflammation of the esophagus that is caused by antigens in both children and adults. It is characterized by esophageal dysfunction and eosinophil infiltration. With increasing incidence and prevalence of the disease, research activities focusing on understanding the disease and development of treatment options are increasing significantly.

Around 15 companies and universities are focusing on developing treatment options for Eosinophilic Esophagitis.

To assist investigators and funding and regulatory organizations, VPA Research has come up with a comprehensive report on Eosinophilic Esophagitis pipeline. The report provides insights into different therapeutic candidates in preclinical, research, discovery, NDA/IND, pre registration, phase 1, phase 2, and phase 3 trials). Drugs under development directly and through combination with other drugs are also included.

Current status, developmental phase, participating companies and entities, recent developments, orphan drug/ fast track/ other designations, drug class are provided for each Eosinophilic Esophagitis pipeline product. Mechanism of Action and the target area of the pipeline product are also provided. Further, clinical and preclinical trials along with results of the trials are also included in the report.

In addition to complete details of each product, the report provides key trends in Eosinophilic Esophagitis pipeline studies. The products under development are categorized according to their development phase, mechanism and company to provide detailed insights into the type of drugs being developed and the stages of development.